TickerFacts.

Eloxx Pharmaceuticals, Inc. (ELOX): Long-Term Debt

Annual figures by period end, from SEC filings.

$1.00M
As of 2025-12-31
-56.0%
3-year compound annual growth
-37.8%
5-year compound annual growth
$13.94M2019-12-31: $13.94M2020-12-31: $10.71M2021-12-31: $11.18M2022-12-31: $11.72M2025-12-31: $1.00M$1.00M
2019-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$1.00Mn/a2026-03-17, Balance as of period end
No annual figure between 2022-12-31 and 2025-12-31.
2022-12-31$11.72M+4.8%2023-03-31, Balance as of period end
2021-12-31$11.18M+4.3%2022-03-30, Balance as of period end
2020-12-31$10.71M-23.1%2021-03-12, Balance as of period end
2019-12-31$13.94Mn/a2020-03-06, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Eloxx Pharmaceuticals, Inc. (ELOX)2025-12-31$1.00Mn/a
Amgen Inc (AMGN)2025-12-31$54.60B-9.1%
Repligen Corp (RGEN)2025-12-31$542.21M+3.2%
Biogen Inc. (BIIB)2025-12-31$6.29B-0.1%
Gilead Sciences, Inc. (GILD)2025-12-31$24.94B-6.6%
AIM ImmunoTech Inc. (AIM)2025-12-31$4.48M+59.5%
Qiagen N.V. (QGEN)2025-12-31$1.65B+18.9%
Agenus Inc (AGEN)2025-12-31$44.66M+34.6%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$2.14B+42.3%

Compare ELOX, AMGN, RGEN, BIIB side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗